A Review of Therapeutic Trials in Multiple Myeloma and Perspectives for Future Trials

摘要: Publisher Summary This chapter provides a review of the therapeutic trials employing cytoxic chemotherapy for treatment multiple myeloma. Melphalan is most widely used agent initial There little evidence to support superiority any drug schedule. Drug doses producing some myelosuppression may give better results than those not myelosuppression. Intravenous melphalan produce slightly higher response rates and longer survival oral form. be because erratic absorption melphalan, which clinically apparent by lack Corticosteroids have activity when alone do prolong survival. When in combination with they add little, if any, advantage compared alone. However, beneficial good risk patients. The limited published data at this time suggests that all alkylating agents tested similar Adriamycin vincristine as single untreated patients although been studied few Cytoxan adriamycin BCNU (1,3-Bis (2 chloroethyl)-l-nitrosourea) are effective second line drugs myeloma alkylator failures. Hexamethylmelamine, pyrazofurin, epipodophyllotoxins being investigated failures activity. Except there antimetabolites.